Xiangxue Signs an Exclusive License Agreement with Athenex to Expand their Existing Partnership

 Xiangxue Signs an Exclusive License Agreement with Athenex to Expand their Existing Partnership

Xiangxue Signs an Exclusive License Agreement with Athenex to Expand their Existing Partnership

Shots:

  • Athenex to receive $30M up front, ~$170M milestones and royalties on sales of licensed products in China, Hong Kong and Macao. Xiangxue to get exclusive license to develop & commercialize Athenex’s oral Paclitaxel, oral Irinotecan and Tirbanibulin ointment for the treatment of actinic keratosis (AK) in licensed territories
  • The collaboration represents the expansion of their existing relationship on KX2-361 for brain tumors and TCR-T immunotherapy and expands Xiangxue’s novel drug portfolio into a pipeline comprising two P-III & one P-I candidate, one with POC data
  • The collaboration emphasizes the global value of Athenex’s advancing pipeline and platform technologies. Additionally, Xiangxue plans to expand its marketing and sales infrastructure to focus on China to capture the full potential of licensed products

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image:  Athenex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post